**** NOW OFFERING COVID-19 SUGAR TOOLS FOR VACCINE AND DRUG DEVELOPMENT **** GlycoDisplay develop novel biopharmaceuticals by modifying glycans. We apply targeted cell engineering allowing display of the glycoforms on drug candidates and drug targets.
GlycoDisplay now launches the first cell-based array platform to produce a range of well-defined recombinant human mucins with custom-designed O-glycans. The cell-based array platform also allows us to display mucins on cell surface and screen binding of e.g. bacterial adhesins and antibodies and dissect binding specificities.
GlycoDisplay Aps was founded 2016 by Professor Henrik Clausen and four cofounders from Copenhagen Center for Glycomics at University of Copenhagen. The team has extensive experience with research in Glycomics, glycoengineering of mammalian cell lines and industry know-how on the development of biologics.
GlycoDisplay develops novel biopharmaceuticals by modifying sugars. The proprietary technology applies targeted cell engineering to display different glycans on cells and proteins. GlycoDisplay is a spin-out from University of Copenhagen, Center for Glycomics, which is world leading within the field of glyco-engineering and glycomics.
